Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast 2023-2033 Research and Markets Wed, Feb 19, 2025, 10:09 AM 3 min read ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

中国生物医药行业或迎来“DeepSeek”时刻，一款由中国生物医药公司自主研发的治疗糖尿病的创新药已正式获准上市。据悉，这是亚洲首个自研人源超长效GLP-1RA药物，凭借起效快、疗效强且持久，具有更长的半衰期及良好的安全性，该药上市后或将挑战司美格鲁 ...

The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...

Taking tiny doses of GLP-1 medication has been touted for weight management, perimenopause symptoms, even longevity. But is ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

Generic drugmaker Granules India is foraying into the peptide segment and contract development and manufacturing organisation (CDMO) business with a ₹192.5 crore (CHF 20 million) acquisition of Swiss ...